SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Price regulation of drugs: Lessons from Germany
5 references·4 citing·34 second hop
Price regulation of drugs: Lessons from Germany (1996)Price regulation of drugs: Lessons from G…Arzneiverordnungs-Report 2001 (2001)Arzneiverordnungs-Report 2001What Happened to Americans' Support for the Clinton Health Plan? (1995)What Happened to Americans' S…Global Budgeting in Germany: Lessons for the United States (1994)Global Budgeting in Germany: …Consumer Demand: A New Approach. (1975)Consumer Demand: A New Approa…Consumer Demand. A New Approach. (1972)Consumer Demand. A New Approa…An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom (2005)An overview of pharmaceutical…Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand (2003)Reference Pricing of Pharmace…Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs. (2001)Impact of reference-based pri…Review of the Literature on Reference Pricing (1999)Review of the Literature on R…Putting People First: How We Can All Change America (1992)The Medically Uninsured — Will They Always Be with Us? (1996)Enhancing the Political Feasibility of Health Reform: A Comparative Analysis of Chile, Colombia, and Mexico (2000)Health and Social Justice (2004)Industrial Market Structure and Economic Performance. (1971)Industrial market structure and economic performance (1990)Effects of Medicaid Drug-Payment Limits on Admission to Hospitals and Nursing Homes (1991)Germany’s Health Care System (1991)The German Health-Care System (1997)Priority-setting and rationing in German health care (1999)Implementing Health Care Reform in Israel: Organizational Response to Perceived Incentives (2003)Pharmaceutical policies: effects of financial incentives for prescribers (2007)Staatswissenschaften und Staatspraxis (2011)Fixing health budgets: experience from Europe and North America (1996)The Strategic Response by Pharmaceutical Firms to the Medicaid Most-Favored-Customer Rules (1996)Pharmaceutical Reference Prices (1998)Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers (2003)Cross-national price differences for pharmaceuticals: how large, and why? (2000)Review of the literature on reference pricing (2000)The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s (2004)Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand (2008)Retail price regulation and innovation: Reference pricing in the pharmaceutical industry (2009)Reference pricing with endogenous generic entry (2016)Does It Pay to Work in the Public Sector? (1998)Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (2005)Impact of Cross-Reference Pricing on Pharmaceutical Prices (2006)Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States (2011)Easy Riders, Joint Production, and Public Goods (1984)Designing Ranking Systems for Hotels on Travel Search Engines by Mining User-Generated and Crowd-Sourced Content (2011)Market Structure and Innovation: A Survey (2016)Hedonic prices, price indices and housing markets (1978)Technological Change and the Environment (2000)Eliciting public preferences for healthcare: a systematic review of techniques (2001)Verbrauch von Zolpidem und Zopiclon auf Privatrezepten zwischen 1993 und 2007 (2009)
this work references cited by second hop

References

  • 1975Consumer Demand: A New Approach.1,235 cited
  • 1972Consumer Demand. A New Approach.1,042 cited
  • 1995What Happened to Americans' Support for the Clinton Health Plan?89 cited
  • 2001Arzneiverordnungs-Report 200174 cited
  • 1994Global Budgeting in Germany: Lessons for the United States54 cited

Cited by

  • 2003Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand73 cited
  • 2005An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom72 cited
  • 2001Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs.60 cited
  • 1999Review of the Literature on Reference Pricing58 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work